Page last updated: 2024-09-02

tadalafil and Prostatic Hyperplasia

tadalafil has been researched along with Prostatic Hyperplasia in 160 studies

Research

Studies (160)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (6.88)	29.6817
2010's	107 (66.88)	24.3611
2020's	42 (26.25)	2.80

Authors

Authors	Studies
Ashida, S; Fukata, S; Fukuhara, H; Inoue, K; Karashima, T; Komatsu, F; Kuno, T; Kuroiwa, H; Saito, M; Sawada, K; Tamura, K; Watanabe, H; Yasuda, M	1
Bhojani, N; Nguyen, DD; Trinh, QD	1
Abdelhafez, AM; Gawad, DA; Hassan, EM; M Youssef, R	1
Matsuo, T; Miyata, Y; Sakai, H	1
Abe, N; Ishikawa, M; Kakizaki, H; Makino, S; Miyauchi, K; Wada, N	1
Antinozzi, C; Aversa, A; Di Luigi, L; Greco, EA; Sgrò, P	1
Blachman-Braun, R; Goberdhan, S; Masterson, TA; Nackeeran, S; Ramasamy, R	1
Abdel Moneim, MM	1
Altunrende, F; Canat, L; Culha, MG; Ermec, B; Kocak, G; Otunctemur, A	1
AbdelRazek, M; Abolyosr, A; Fathi, A; Hassan, A; Mhammed, O; Talaat, M	1
Fujihara, A; Harikai, S; Hirahara, N; Ukimura, O; Ushijima, S; Yamada, Y	1
Fujimoto, K; Gotoh, D; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Torimoto, K	1
Exintaris, B; Middendorff, R; Mietens, A; Seidensticker, M; Tasch, S	1
Abdelaziz, A; Batekh, AE; Emad, N; Galal, M; Hussien, M; Karem, M; Moukhtar, DA; Salem, H	1
Armin, A; Khoshdel, AR; Poopak, A; Samzadeh, M; Zahir, M	1
Darweish, E; Mohamed, AR	1
Abbaszadeh Hasiri, M; Ahrari Khafi, MS; Dearakhshandeh, N; Golchin-Rad, K; Mogheiseh, A; Nazifi, S	2
Atan, A; Bulut, EC; Doğan, AE; Polat, F; Tokuçoğlu, H; Ünsal, A; Yeşil, S	1
Kamalov, AA; Nizov, AN	1
Akamatsu, S; Goto, T; Kobayashi, T; Matsubara, K; Matsui, Y; Negoro, H; Ogawa, O; Omura, T; Terada, N; Yamamoto, T; Yonezawa, A	1
Hiramatsu, I; Honda, S; Horie, S; Ishikawa, K; Iwata, S; Mitsuhashi, I; Mizuno, T; Nagashima, Y; Noto, K; Nozaki, T; Ogishima, T; Shigeta, Y; Shirai, M; Soejima, M; Sugimura, S; Takasu, J; Tsujimura, A; Uesaka, Y; Yoshiyama, A	1
Amano, T	1
Tanaka, T	1
Chapple, C; De Nunzio, C; Frizzi, J; Gacci, M; Gravas, S; Kaplan, SA; Maggi, M; McVary, KT; Saleh, O; Sebastianelli, A; Serni, S; Spatafora, P; Tubaro, A; Vignozzi, L	1
Rezk, MR; Tantawy, MA; Wadie, M; Weshahy, SA	1
Ahn, ST; Jeong, HG; Kim, JW; Lee, DH; Moon, DG; Oh, MM; Park, HS	1
Fuse, M; Kaga, K; Kageyama, S; Sakata, K; Tokunaga, S; Yamanishi, T; Yokoyama, T	1
Kaputovskij, AA	1
Cai, Z; Li, H; Ma, C; Zhang, J	1
Huang, H; Huang, WP; Ye, XT; Zhang, FY	1
Cai, Z; Li, H; Ma, C; Xiong, J; Zhang, J	1
Chen, X; Guo, B; Hou, H; Liu, M; Wang, M; Zhang, Z	1
Burnett, AL; Feng, Q; Hairston, JC; Johnston, KM; Lozano-Ortega, G; Nimke, D; Walker, DR	1
Eto, M; Mimata, H; Miyazato, M; Nishii, H; Oshiro, T; Saito, S; Sumino, Y; Takahashi, R; Yoshida, M	1
Gupta, S; Singh, I; Tk, A	1
Borisov, VV	1
Higashi, Y; Kamada, S; Kataoka, T; Nagao, Y; Saito, M; Shimizu, S; Shimizu, T	1
Izumi, K; Kadono, Y; Kawaguchi, S; Mizokami, A; Nohara, T; Shigehara, K; Shimamura, M; Shouda, R	1
Chapple, C; Gacci, M; Gravas, S; Kaplan, S; McVary, KT; Morselli, S; Sebastianelli, A; Serni, S; Spatafora, P; Vignozzi, L	1
Chapple, C; Gacci, M; Gemma, L; Gravas, S; Kaplan, SA; Liaci, A; Maggi, M; McVary, KT; Morselli, S; Sebastianelli, A; Serni, S; Spatafora, P; Vignozzi, L; Zaccaro, C	1
Higashi, Y; Kuwahara, Y; Nakamura, K; Shimura, H; Takeda, M; Tsukamoto, T; Watanabe, N	1
Fukazawa, A; Hashida, I; Iijima, K; Ishizuka, O; Kato, H; Koiwai, K; Minagawa, T; Ogawa, T; Oguchi, T; Saitou, T	1
Kosivtsova, MA; Kostromeev, SA; Statsenko, ME; Turkina, SV; Tyschenko, IA	1
Deguchi, T; Fujihiro, S; Kikuchi, M; Masue, T; Miwa, K; Moriyama, Y; Nakai, C; Nishino, Y	1
Kinoshita, H; Matsuda, T; Shimada, S; Taguchi, M; Yoshida, T	1
Origasa, H; Seki, N; Yoshida, M	1
Ahn, TY; Hyun, JS; Jung, J; Kim, SW; Lee, SW; Min, KS; Moon, DG; Moon, KH; Park, JK; Park, K; Park, NC; Ryu, JK; Son, H; Yang, DY; Yang, SK	1
Amano, T; Earle, C; Imao, T; Kishikage, T; Matsumoto, Y	1
Murakami, M; Ozeki, A; Suzuki, N; Yokoyama, O	1
Kaplan, SA	4
Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Matsuo, K; Yamamoto, T	1
Eto, M; Fujimoto, N; Mimata, H; Miyazato, M; Nishii, H; Onzuka, M; Oshiro, T; Saito, S; Sumino, Y; Takahashi, R; Takayama, K	1
Bao, Y; Cui, Y; Duan, L; Liu, J; Wang, Y	1
Burgio, G; Calogero, AE; Cannarella, R; Condorelli, RA; La Vignera, S	1
Arai, Y; Fukushi, T; Kaiho, Y; Kawasaki, Y; Koyama, J; Kyan, A; Sato, T	1
Ameli, M; Ameli, Z; Baghani Aval, H	1
Funahashi, Y; Gotoh, M; Kato, M; Majima, T; Matsukawa, Y; Sassa, N; Takai, S; Yamamoto, T	1
Griebling, TL	1
Anjiki, H; Hagiwara, K; Hayashida, M; Kurosawa, K; Nagamoto, S; Ogawa, K; Oka, S; Okaneya, T; Sakaguchi, K; Urakami, S; Yano, A	1
Dai, Y; Jiann, BP; Li, H; Li, P; Lou, Y; Park, HJ; Viktrup, L; Ye, Z; Zhang, X; Zhang, Z	1
Kitta, T	1
Miura, K; Mizushima, A; Watanabe, D; Yamashita, A	1
Arai, Y; Fujii, S; Goto, T; Hayashi, N; Ito, A; Izumi, H; Kawamorita, N; Kawasaki, Y; Koyama, J; Mitsuzuka, K; Sato, T; Shimada, S; Yamashita, S	1
Funahashi, Y; Gotoh, M; Inoue, S; Kanada, Y; Kato, M; Majima, T; Matsukawa, Y; Takai, S; Yamamoto, T	1
Hashimoto, Y; Hatakeyama, S; Matsumoto, T; Narita, T; Ohyama, C; Yoneyama, T	1
De Nucci, G; Mónica, FZ	1
Bulygin, KV; Galimov, SN; Galimova, EF; Gaysina, GG; Nikitina, IL; Pavlov, VN	1
Yuan, RQ	1
Andersson, KE; Gratzke, C; Herlemann, A; Sievert, KD	1
Baye, J; Cantrell, MA; Vouri, SM	1
de la Taille, A; Doridot, G; Giuliano, F; Rouprêt, M	1
Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Nesi, G; Santi, R; Sebastianelli, A; Serni, S; Vignozzi, L	1
Brock, GB; Lee, KC	1
Esler, A; Porst, H; Roehrborn, CG; Secrest, RJ; Viktrup, L	1
Dong, Y; Han, C; Hao, L; Shi, Z; Wang, G; Zhang, Z	1
Brock, G; Broderick, G; Roehrborn, CG; Viktrup, L; Wong, D; Xu, L	1
Casabé, A; Da Pozzo, LF; Henderson, RJ; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L; Wong, DG; Zepeda, S	1
Brock, GB; Donatucci, C; McVary, KT; Ni, X; Roehrborn, CG; Viktrup, L; Watts, S; Wong, DG	1
Mandal, AK; Mete, UK; Singh, DV; Singh, SK	1
Bechara, A; Casabe, A; Cobreros, C; Rodriguez Baigorri, G	1
Carson, CC; Kissel, J; Rosenberg, M; Wong, DG	1
Chapple, C; Cox, D; Esler, A; Oelke, M; Roehrborn, CG; Viktrup, L	1
Cox, D; Mamoulakis, C; Oelke, M; Ruff, D; Viktrup, L; Weiss, JP	1
Lee, SW; Morisaki, Y; Murakami, M; Takeda, M; Viktrup, L; Yokoyama, O	1
Akino, H	1
Baygani, SK; Giuliano, F; Melby, T; Oelke, M; Sontag, A	1
Bolyakov, A; Cox, D; Da Pozzo, L; Efros, M; Esler, A; Frauscher, F; Kaminetsky, J; Paduch, DA; Pinggera, GM	1
Brock, GB; Dickson, R; Henneges, C; Herschorn, S; Nickel, JC; Viktrup, L	1
Benigni, F; Briganti, A; Buono, R; Castiglione, F; Freschi, M; Hedlund, P; La Croce, G; Montorsi, F; Moschini, M; Villa, L	1
Chapple, CR; Henneges, C; Ilo, D; McVary, K; Roehrborn, CG; Viktrup, L	1
Büttner, H; Esen, A; Glina, S; Henneges, C; Plekhanov, A; Roehrborn, CG; Sorsaburu, S; Viktrup, L	1
Madersbacher, S; Schauer, I	1
Baygani, SK; Donatucci, CF; Oelke, M; Shinghal, R; Sontag, A	1
De Nunzio, C; Tubaro, A	1
Morisaki, Y; Murakami, M; Nishizawa, O; Takeda, M; Viktrup, L; Yokoyama, O; Yoshida, M	1
Casabé, A; Glina, S; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L	1
Oh-Oka, H	1
Masumori, N	1
Büttner, H; D'Anzeo, G; Fusco, F; Henneges, C; Nickel, JC; Rossi, A	1
Brock, GB; Büttner, H; Esler, A; Maggi, M; Mulhall, JP; Oelke, M; Rosenberg, MT; Vlachopoulos, C	1
Egan, KB; McVary, K; Miner, MM; Ni, X; Roehrborn, CG; Rosen, RC; Suh, M; Wittert, G; Wong, DG	1
Egan, KB; Miner, MM; Ni, X; Roehrborn, CG; Rosen, RC; Wong, DG	1
Baygani, S; Brock, GB; Donatucci, CF; Glina, S; Maggi, M; Mulhall, JP	1
Baygani, S; Clouth, J; Donatucci, CF; Henneges, C; McVary, KT; Oelke, M; Peterson, A; Wong, D	1
Fukagai, T; Hayashi, K; Igarashi, A; Koshikiya, A; Morita, M; Sasaki, H	1
Fallah-Karkan, M; Hassanzadeh-Hadad, A; Karami, H	1
Büttner, H; Oelke, M; Takita, Y; Viktrup, L; Wagg, A	1
Fujii, T; Fukumoto, K; Hara, R; Miyaji, Y; Nagai, A	1
Fukimbara, S; Odani, M; Sato, T	1
Fukagai, T; Hayashi, K; Igarashi, A; Ishikawa, K; Koshikiya, A; Morita, M; Sasaki, H	1
Madersbacher, S	1
Bechara, A; Casabé, A; Dedola, P; Haime, S; Hernández, C; Rey, H; Romano, S	1
Elion-Mboussa, A; McVary, KT; Roehrborn, CG; Viktrup, L	1
Hauzeur, C; Roumeguère, T; Schulman, C; Vanhaeverbeek, M; Wespes, E; Zouaoui Boudjeltia, K	1
Volpe, A	1
Elion-Mboussa, A; McVary, KT; Montorsi, F; Porst, H; Sutherland, P; Viktrup, L; Wolka, AM	1
Bernich, R; Bertolotto, M; Cova, MA; Savoca, G; Trincia, E; Zappetti, R	1
Auerbach, SM; Elion-Mboussa, A; Kaminetsky, JC; Montelongo, RM; Roehrborn, CG; Viktrup, L	1
Dmochowski, R; Kaminetsky, J; Klise, S; Kraus, S; Roehrborn, C; Xu, L	2
Brock, GB; Broderick, GA; Elion-Mboussa, A; Roehrborn, CG; Viktrup, L; Watts, SD	1
Dmochowski, RR; Gomelsky, A	1
de la Rosette, JJ	1
Berger, P; Pernkopf, D; Plas, E; Sampson, N; Untergasser, G; Zenzmaier, C	1
Choi, SB; Jeon, JH; Kang, KK; Kim, SH; Lee, SW; Park, JK; Zhao, C	1
Angalakuditi, M; Hayes, RP; O'Leary, MP; Seifert, RF; Viktrup, L	1
Brock, GB; Donatucci, CF; Elion-Mboussa, A; Goldfischer, ER; Kissel, JD; Pommerville, PJ; Viktrup, L	1
Andersson, KE; de Groat, WC; Lue, TF; Maggi, M; McVary, KT; Melby, T; Roehrborn, CG; Viktrup, L; Wyndaele, JJ	1
Bergamasco, L; Gualà, L; Maselli, G; Pace, G; Silvestri, V; Vicentini, C	1
Casabé, AR; Kim, ED; Mirone, V; Porst, H; Secrest, RJ; Sundin, DP; Viktrup, L; Xu, L	1
Auerbach, S; Costa, P; Egerdie, RB; Esler, AL; Garza, MS; Roehrborn, CG; Secrest, RJ; Wong, DG	1
Helfand, BT; Mazur, DJ; McVary, KT	1
Cox, D; Giuliano, F; Mirone, V; Oelke, M; Viktrup, L; Xu, L	1
Brady, E; Clark, WR; Dgetluck, N; Goldfischer, E; Klise, SR; Kowalczyk, JJ; Shane, MA	1
Wyllie, MG	1
Chapple, CR	1
Carini, M; Corona, G; Gacci, M; Kaplan, SA; Maggi, M; McVary, KT; Mirone, V; Roehrborn, CG; Salvi, M; Serni, S; Vignozzi, L	1
Allona, A; Angulo, J; Cuevas, P; Fernández, A; La Fuente, JM; Moncada, I; Sáenz de Tejada, I	1
Imaoka, T; Kim, SC; Morisaki, Y; Viktrup, L; Wang, CJ; Yokoyama, O; Yoshida, M	1
Gacci, M	1
Curran, MP	1
Cerqueira, JB; de Moraes, MO; Jamacaru, FV; Josino, IR; Nogueira, EA; Regadas, RP; Reges, R; Silva, LF; Sucupira, DG	1
Giuliano, F; Viktrup, L	1
Cox, D; Giuliano, F; Hatzimouratidis, K; Jungwirth, A; Oelke, M; Viktrup, L; Watts, S	1
Miller, MS	1
Gonzalez, RR; Kaplan, SA	1
van Driel, MF	1
Hütter, J; Sandner, P; Stelte-Ludwig, B; Tinel, H	1
Auerbach, SM; Denes, BS; Esler, A; Kaminetsky, JC; McVary, KT; Roehrborn, CG; Sides, GD; Wachs, B; Young, JM	1
Bischoff, E; Huetter, J; Neuser, D; Sandner, P; Stelte-Ludwig, B; Tinel, H; Ulbrich, E	1

Reviews

26 review(s) available for tadalafil and Prostatic Hyperplasia

Article	Year
Tadalafil and Steroid Hormones Interactions in Adipose, Bone and Prostate Tissues: Focus on Translational Perspectives. International journal of molecular sciences, 2022, Apr-11, Volume: 23, Issue:8 Topics: Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Hormones; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Steroids; Tadalafil; Treatment Outcome	2022
[Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction]. Urologiia (Moscow, Russia : 1999), 2019, 12-31, Issue:6 Topics: Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Vasodilator Agents	2019
Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis. BioMed research international, 2020, Volume: 2020 Topics: Bayes Theorem; Databases, Factual; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Safety; Sildenafil Citrate; Tadalafil; Tamsulosin; Treatment Outcome	2020
Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. Medical science monitor : international medical journal of experimental and clinical research, 2020, Apr-24, Volume: 26 Topics: Adrenergic alpha-1 Receptor Antagonists; Double-Blind Method; Drug Therapy, Combination; Humans; Hyperplasia; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Tadalafil; Tamsulosin; Treatment Outcome	2020
Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. Current urology reports, 2020, Oct-27, Volume: 21, Issue:12 Topics: Combined Modality Therapy; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents	2020
Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. Lower urinary tract symptoms, 2018, Volume: 10, Issue:1 Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Severity of Illness Index; Tadalafil	2018
Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. The aging male : the official journal of the International Society for the Study of the Aging Male, 2018, Volume: 21, Issue:4 Topics: Adrenergic alpha-1 Receptor Antagonists; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2018
Tadalafil for the treatment of benign prostatic hyperplasia. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:8 Topics: 5-alpha Reductase Inhibitors; Animals; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Tadalafil; Treatment Outcome	2019
[Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia]. Zhonghua nan ke xue = National journal of andrology, 2012, Volume: 18, Issue:12 Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Retrospective Studies; Tadalafil; Treatment Outcome	2012
[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors]. Der Urologe. Ausg. A, 2013, Volume: 52, Issue:2 Topics: Carbolines; Controlled Clinical Trials as Topic; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Urodynamics; Vardenafil Dihydrochloride	2013
Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. Pharmacotherapy, 2013, Volume: 33, Issue:6 Topics: Carbolines; Drug Approval; Erectile Dysfunction; Half-Life; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; United States; United States Food and Drug Administration	2013
[Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23, Issue:5 Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil	2013
Daily dosing of PDE5 inhibitors: where does it fit in? Current urology reports, 2013, Volume: 14, Issue:4 Topics: Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2013
Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. Urologia internationalis, 2013, Volume: 91, Issue:1 Topics: Carbolines; Erectile Dysfunction; Humans; Male; Patient Safety; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Risk; Tadalafil; Treatment Outcome; Urinary Tract; Urologic Diseases; Urological Agents	2013
Tadalafil - a therapeutic option in the management of BPH-LUTS. International journal of clinical practice, 2014, Volume: 68, Issue:1 Topics: Aged; Carbolines; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Multicenter Studies as Topic; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Tadalafil; Treatment Outcome; Urodynamics; Urological Agents	2014
Tadalafil and benign prostatic hypertrophy. Too risky. Prescrire international, 2014, Volume: 23, Issue:148 Topics: Carbolines; Drug Interactions; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Risk Assessment; Risk Factors; Tadalafil; Treatment Outcome; Urological Agents	2014
Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015. Current opinion in urology, 2015, Volume: 25, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adrenergic beta-3 Receptor Agonists; Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Muscarinic Antagonists; Prostatic Hyperplasia; Tadalafil; Urological Agents	2015
Benign prostatic hyperplasia in 2014: Innovations in medical and surgical treatment. Nature reviews. Urology, 2015, Volume: 12, Issue:2 Topics: Acetylcholine Release Inhibitors; Botulinum Toxins, Type A; Drug Combinations; Humans; Laser Therapy; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Solifenacin Succinate; Sulfonamides; Tadalafil; Tamsulosin; Transurethral Resection of Prostate; Urological Agents	2015
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU international, 2009, Volume: 104, Issue:4 Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Quality of Life; Quinazolines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride	2009
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourology and urodynamics, 2011, Volume: 30, Issue:3 Topics: Carbolines; Evidence-Based Medicine; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Recovery of Function; Signal Transduction; Tadalafil; Treatment Outcome; Urodynamics; Urologic Diseases	2011
Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men. The Urologic clinics of North America, 2012, Volume: 39, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Aging; Carbolines; Disease Progression; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Men's Health; Middle Aged; Neurotransmitter Agents; Piperazines; Prognosis; Prostatic Hyperplasia; Purines; Receptors, Neurotransmitter; Risk Assessment; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride	2012
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European urology, 2012, Volume: 61, Issue:5 Topics: Adrenergic alpha-Antagonists; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostatic Hyperplasia; Purines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride	2012
Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. Drugs & aging, 2012, Volume: 29, Issue:9 Topics: Carbolines; Erectile Dysfunction; Humans; Male; Prostatic Hyperplasia; Safety; Tadalafil	2012
Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. The Annals of pharmacotherapy, 2013, Volume: 47, Issue:2 Topics: Adrenergic alpha-Antagonists; Carbolines; Drug Resistance; Drug Therapy, Combination; Erectile Dysfunction; Humans; Imidazoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Prostate; Prostatic Hyperplasia; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents	2013
Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert opinion on drug metabolism & toxicology, 2006, Volume: 2, Issue:4 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Humans; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Prostatic Hyperplasia; Tadalafil; Urologic Diseases	2006
[Phosphodiesterase inhibitors: effectiveness and new applications]. Nederlands tijdschrift voor geneeskunde, 2006, Jul-22, Volume: 150, Issue:29 Topics: Carbolines; Coronary Disease; Erectile Dysfunction; Humans; Hypertension; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride	2006

Trials

58 trial(s) available for tadalafil and Prostatic Hyperplasia

Article	Year
Editorial Comment to Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: A double-blinded, randomized, pilot clinical trial. International journal of urology : official journal of the Japanese Urological Association, 2022, Volume: 29, Issue:6 Topics: Double-Blind Method; Drug Therapy, Combination; Herbal Medicine; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Tamsulosin; Treatment Outcome	2022
Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World journal of urology, 2022, Volume: 40, Issue:8 Topics: Erectile Dysfunction; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome	2022
Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial. Urology journal, 2023, Jul-26, Volume: 20, Issue:4 Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Sildenafil Citrate; Tadalafil; Treatment Outcome; Urinary Retention	2023
Changes in the oxidative stress factors and inflammatory proteins following the treatment of BPH-induced dogs with an anti-proliferative agent called tadalafil. Journal of veterinary pharmacology and therapeutics, 2019, Volume: 42, Issue:6 Topics: Androgens; Animals; Contraceptive Agents, Hormonal; Dog Diseases; Dogs; Estradiol; Gene Expression Regulation; Inflammation; Male; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Testosterone	2019
The efficacy of Tadalafil 5mg in the treatment of lower urinary tract symptoms in patients where alpha blocker treatments have failed in terms of lower urinary tract symptoms. Archivos espanoles de urologia, 2019, Volume: 72, Issue:7 Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2019
Add-on effects of tadalafil in tamsulosin-treated patients with small benign prostatic enlargement: A randomized, placebo-controlled, double-blind, crossover study. Neurourology and urodynamics, 2020, Volume: 39, Issue:1 Topics: Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents	2020
Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs. Theriogenology, 2020, Jan-15, Volume: 142 Topics: Animals; Combined Modality Therapy; Disease Models, Animal; Dog Diseases; Dogs; Male; Orchiectomy; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2020
A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourology and urodynamics, 2020, Volume: 39, Issue:2 Topics: Acetanilides; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urination; Urological Agents	2020
[Therapeutic effect of tadalafil on lower urinary tract symptoms with erectile dysfunction]. Zhonghua nan ke xue = National journal of andrology, 2019, Volume: 25, Issue:6 Topics: Carbolines; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Tamsulosin; Treatment Outcome	2019
Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. International journal of clinical practice, 2020, Volume: 74, Issue:8 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents	2020
Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial. International journal of urology : official journal of the Japanese Urological Association, 2021, Volume: 28, Issue:4 Topics: Brachytherapy; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Sulfonamides; Tadalafil; Treatment Outcome	2021
Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. Lower urinary tract symptoms, 2017, Volume: 9, Issue:3 Topics: Aged; Drug Administration Schedule; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urological Agents	2017
Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial. The journal of sexual medicine, 2017, Volume: 14, Issue:8 Topics: Aged; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents	2017
Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study. International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:3 Topics: Aged; Aged, 80 and over; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urination; Urodynamics	2018
Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trial. Urologia, 2018, Volume: 85, Issue:2 Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Aged; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Tamsulosin; Treatment Outcome; Urinary Retention	2018
Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α Lower urinary tract symptoms, 2019, Volume: 11, Issue:3 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Humans; Male; Middle Aged; Pilot Projects; Prostatic Hyperplasia; Prostatism; Severity of Illness Index; Solifenacin Succinate; Tadalafil; Urological Agents	2019
Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled s International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:2 Topics: Aged; China; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Placebos; Prostatic Hyperplasia; Republic of Korea; Severity of Illness Index; Tadalafil; Taiwan; Tamsulosin; Treatment Outcome	2019
Evaluating the effects of switching from dutasteride to tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms: A randomized, open-label, multicenter study. International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Dose-Response Relationship, Drug; Drug Substitution; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Severity of Illness Index; Sexual Dysfunction, Physiological; Tadalafil; Treatment Outcome	2019
PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. The Prostate, 2013, Volume: 73, Issue:13 Topics: Aged; Aged, 80 and over; Carbolines; Cyclic GMP; Double-Blind Method; Humans; Imidazoles; Inflammation; Interleukin-8; Lower Urinary Tract Symptoms; Male; Middle Aged; Myofibroblasts; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Prostate; Prostatic Hyperplasia; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride	2013
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical stu The journal of sexual medicine, 2013, Volume: 10, Issue:8 Topics: Aged; Carbolines; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Placebos; Prostate-Specific Antigen; Prostatic Hyperplasia; Tadalafil; Urination	2013
Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. BJU international, 2013, Volume: 112, Issue:7 Topics: Carbolines; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2013
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. The Journal of urology, 2014, Volume: 191, Issue:3 Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urological Agents	2014
A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. The journal of sexual medicine, 2014, Volume: 11, Issue:1 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urinary Retention	2014
Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. The Journal of urology, 2014, Volume: 191, Issue:4 Topics: Carbolines; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Urination	2014
Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. World journal of urology, 2014, Volume: 32, Issue:5 Topics: Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Nocturia; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2014
Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:7 Topics: Aged; Asian People; Carbolines; Double-Blind Method; Humans; Japan; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Placebos; Prostatic Hyperplasia; Republic of Korea; Tadalafil; Treatment Outcome	2014
Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study. BJU international, 2014, Volume: 114, Issue:4 Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Satisfaction; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urological Agents	2014
Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology, 2014, Volume: 84, Issue:2 Topics: Aged; Carbolines; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostate; Prostatic Hyperplasia; Regional Blood Flow; Tadalafil	2014
Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia – integrated data from 1,499 study participants. BJU international, 2015, Volume: 115, Issue:5 Topics: Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Remission Induction; Tadalafil	2015
Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. The journal of sexual medicine, 2015, Volume: 12, Issue:1 Topics: Carbolines; Coitus; Comorbidity; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2015
Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. The Journal of urology, 2015, Volume: 193, Issue:5 Topics: Carbolines; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Remission Induction; Tadalafil; Time Factors	2015
Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies. International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:4 Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Asian People; Double-Blind Method; Humans; Male; Middle Aged; Organ Size; Prostate; Prostatic Hyperplasia; Prostatism; Severity of Illness Index; Tadalafil; Taiwan; Urological Agents	2015
Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing f International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:6 Topics: 5-alpha Reductase Inhibitors; Aged; Double-Blind Method; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Organ Size; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatism; Severity of Illness Index; Tadalafil	2015
Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an International journal of clinical practice, 2015, Volume: 69, Issue:12 Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Risk Factors; Tadalafil; Vasodilator Agents	2015
Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. BJU international, 2016, Volume: 118, Issue:1 Topics: Aged; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Time Factors; Treatment Outcome	2016
Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Tria The journal of sexual medicine, 2016, Volume: 13, Issue:5 Topics: Adult; Aged; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Testosterone; Treatment Outcome; Vasodilator Agents	2016
Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperpl The Journal of urology, 2016, Volume: 196, Issue:3 Topics: Aged; Dose-Response Relationship, Drug; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Urination	2016
Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial. Urology journal, 2016, 12-08, Volume: 13, Issue:6 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Single-Blind Method; Sulfonamides; Tadalafil; Tamsulosin	2016
Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. The journal of sexual medicine, 2008, Volume: 5, Issue:9 Topics: Aged; Carbolines; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Retention	2008
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. The Journal of urology, 2008, Volume: 180, Issue:4 Topics: Administration, Oral; Aged; Carbolines; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Reference Values; Severity of Illness Index; Tadalafil; Treatment Outcome; Urination Disorders; Urodynamics	2008
Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. European urology, 2009, Volume: 56, Issue:4 Topics: Aged; Carbolines; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Tadalafil	2009
Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU international, 2010, Volume: 105, Issue:4 Topics: Aged; Carbolines; Dose-Response Relationship, Drug; Epidemiologic Methods; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil; Treatment Outcome; Urination; Urodynamics	2010
Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. The Journal of urology, 2010, Volume: 183, Issue:3 Topics: Carbolines; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil; Time Factors; Urodynamics	2010
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology, 2010, Volume: 75, Issue:6 Topics: Aged; Carbolines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Phosphodiesterase Inhibitors; Probability; Prostatic Hyperplasia; Prostatism; Quality of Life; Reference Values; Risk Assessment; Severity of Illness Index; Tadalafil; Treatment Outcome; Urination Disorders; Urodynamics	2010
Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU international, 2011, Volume: 107, Issue:12 Topics: Aged; Carbolines; Erectile Dysfunction; Feasibility Studies; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Pyrimidines; Sulfonamides; Tadalafil; Treatment Outcome	2011
Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies. Health and quality of life outcomes, 2010, Nov-12, Volume: 8 Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Sickness Impact Profile; Statistics, Nonparametric; Surveys and Questionnaires; Tadalafil; Time Factors; Treatment Outcome	2010
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU international, 2011, Volume: 107, Issue:7 Topics: Aged; Aged, 80 and over; Carbolines; Drug Administration Schedule; Epidemiologic Methods; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil; Treatment Outcome	2011
Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: a prospective randomized study. International journal of urology : official journal of the Japanese Urological Association, 2011, Volume: 18, Issue:7 Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Prospective Studies; Prostatic Hyperplasia; Quinuclidines; Solifenacin Succinate; Surveys and Questionnaires; Tadalafil; Tetrahydroisoquinolines; Therapeutics; Urination Disorders; Urodynamics	2011
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. European urology, 2011, Volume: 60, Issue:5 Topics: Aged; Analysis of Variance; Argentina; Carbolines; Double-Blind Method; Drug Administration Schedule; Europe; Humans; Lower Urinary Tract Symptoms; Male; Mexico; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Placebos; Prostatic Hyperplasia; Tadalafil; Time Factors; Treatment Outcome; United States; Urination; Urodynamics	2011
Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. The journal of sexual medicine, 2012, Volume: 9, Issue:1 Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Surveys and Questionnaires; Tadalafil; Treatment Outcome	2012
Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. European urology, 2012, Volume: 61, Issue:5 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Satisfaction; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Vasodilator Agents	2012
Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial. Urology, 2012, Volume: 79, Issue:4 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Carbolines; Double-Blind Method; Doxazosin; Hemodynamics; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2012
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:2 Topics: Administration, Oral; Aged; Analysis of Variance; Carbolines; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Patient Selection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Reference Values; Risk Assessment; Severity of Illness Index; Sulfonamides; Tadalafil; Tamsulosin; Treatment Outcome; Urination; Urodynamics	2013
Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. International urology and nephrology, 2013, Volume: 45, Issue:1 Topics: Adrenergic alpha-1 Receptor Antagonists; Carbolines; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Sulfonamides; Tadalafil; Tamsulosin; Urinary Bladder, Overactive; Urination; Urodynamics	2013
Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. The Journal of urology, 2013, Volume: 189, Issue:1 Suppl Topics: Carbolines; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Time Factors; Urodynamics	2013
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin The journal of sexual medicine, 2013, Volume: 10, Issue:3 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Carbolines; Double-Blind Method; Drug Administration Schedule; Ejaculation; Erectile Dysfunction; Humans; Male; Middle Aged; Orgasm; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Sulfonamides; Surveys and Questionnaires; Tadalafil; Tamsulosin	2013
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of urology, 2007, Volume: 177, Issue:4 Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil	2007
[PDE5 inhibitors in treatment of benign prostatic syndrome]. Der Urologe. Ausg. A, 2007, Volume: 46, Issue:9 Topics: Animals; Carbolines; Cell Division; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Isometric Contraction; Male; Middle Aged; Muscle, Smooth; Organ Culture Techniques; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Prostate; Prostatic Hyperplasia; Purines; Rats; Sildenafil Citrate; Stromal Cells; Sulfones; Syndrome; Tadalafil; Triazines; Urethra; Urinary Bladder; Vardenafil Dihydrochloride	2007

Other Studies

76 other study(ies) available for tadalafil and Prostatic Hyperplasia

Article	Year
Tadalafil 5 mg Once Daily Improved Each IPSS Subscore, QOL, and Nocturia in Elderly BPH Patients over 70 Years Old in a Real-World Clinical Setting. Urologia internationalis, 2022, Volume: 106, Issue:10 Topics: Aged; Humans; Lower Urinary Tract Symptoms; Male; Nocturia; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome	2022
Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade. European urology, 2022, Volume: 81, Issue:4 Topics: Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urinary Tract	2022
Assay of new combination of tamsulosin and tadalafil using synchronous spectrofluorimetric method coupled with mathematical tools. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2022, Apr-15, Volume: 271 Topics: Drug Therapy, Combination; Humans; Prostatic Hyperplasia; Spectrometry, Fluorescence; Tadalafil; Tamsulosin	2022
Dutasteride add-on treatment to tadalafil for patients with benign prostatic enlargement is similarly effective as dutasteride add-on treatment to alpha blocker: a propensity-score matching analysis. International urology and nephrology, 2022, Volume: 54, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome	2022
Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms? World journal of urology, 2022, Volume: 40, Issue:7 Topics: Adrenergic alpha-Antagonists; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Venous Thromboembolism	2022
Green & Sensitive pH-dependent Spectrofluorimetric Assay of Tamsulosin Hydrochloride and Tadalafil in their New Combined Formulation for Benign Prostatic Hyperplasia: Application to Spiked Human Plasma. Journal of fluorescence, 2022, Volume: 32, Issue:4 Topics: Humans; Hydrogen-Ion Concentration; Male; Prostatic Hyperplasia; Spectrometry, Fluorescence; Tadalafil; Tamsulosin	2022
The effect of vitamin D replacement in patients with lower urinary tract complaint/erectile dysfunction resistant to Tadalafil 5 mg treatment: A pilot clinical study. Andrologia, 2022, Volume: 54, Issue:8 Topics: Adult; Carbolines; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urinary Tract; Vitamin D; Vitamins	2022
Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms. Lower urinary tract symptoms, 2022, Volume: 14, Issue:5 Topics: Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive	2022
Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC research notes, 2022, Sep-05, Volume: 15, Issue:1 Topics: Aged; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Tadalafil; Urinary Bladder, Overactive	2022
A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH. The Medical letter on drugs and therapeutics, 2022, 09-05, Volume: 64, Issue:1658 Topics: Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia; Tadalafil	2022
Treatment of benign prostatic hyperplasia and abnormal ejaculation: live imaging reveals tamsulosin - but not tadalafil - induced dysfunction of prostate, seminal vesicles and epididymis. Reproduction (Cambridge, England), 2022, 12-01, Volume: 164, Issue:6 Topics: Ejaculation; Epididymis; Humans; Male; Norepinephrine; Prostate; Prostatic Hyperplasia; Seminal Vesicles; Sulfonamides; Tadalafil; Tamsulosin	2022
Synchronous fluorescence as a green and selective method for the simultaneous determination of finasteride and tadalafil in dosage form and spiked human plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2023, Oct-15, Volume: 299 Topics: Capsules; Finasteride; Fluorescence; Humans; Male; Prostatic Hyperplasia; Spectrometry, Fluorescence; Tadalafil	2023
Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2024, Jan-15, Volume: 305 Topics: Erectile Dysfunction; Humans; Male; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2024
[Efficiency of phosphodiesterase-5 inhibitors for treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia and concomitant erectile dysfunction]. Urologiia (Moscow, Russia : 1999), 2019, Issue:4 Topics: Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Moscow; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome	2019
Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. International journal of urology : official journal of the Japanese Urological Association, 2020, Volume: 27, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatitis; Retrospective Studies; Severity of Illness Index; Tadalafil	2020
Editorial Comment from Dr Amano to Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. International journal of urology : official journal of the Japanese Urological Association, 2020, Volume: 27, Issue:1 Topics: Humans; Male; Pelvic Pain; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatitis; Tadalafil	2020
Editorial Comment from Dr Tanaka to Tadalafil is sufficiently effective for severe chronic prostatitis/chronic pelvic pain syndrome in patients with benign prostatic hyperplasia. International journal of urology : official journal of the Japanese Urological Association, 2020, Volume: 27, Issue:1 Topics: Humans; Male; Pelvic Pain; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatitis; Tadalafil	2020
Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. European urology focus, 2021, Volume: 7, Issue:2 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Tamsulosin; Urological Agents	2021
Smart spectrophotometric assessment of tamsulosin hydrochloride and tadalafil in their new pharmaceutical formulation for treatment of benign prostatic hyperplasia and erectile dysfunction. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2020, Feb-15, Volume: 227 Topics: Adrenergic alpha-1 Receptor Antagonists; Capsules; Drug Combinations; Drug Compounding; Erectile Dysfunction; Humans; Limit of Detection; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Spectrophotometry; Tadalafil; Tamsulosin	2020
Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction. Investigative and clinical urology, 2020, Volume: 61, Issue:1 Topics: Age Factors; Aged; Drug Combinations; Erectile Dysfunction; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Prostatic Hyperplasia; Retrospective Studies; Tadalafil; Tamsulosin; Treatment Failure; Urological Agents	2020
To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia: A protocol for systematic review and meta analysis. Medicine, 2020, Volume: 99, Issue:3 Topics: Adrenergic alpha-1 Receptor Antagonists; Bayes Theorem; Drug Therapy, Combination; Humans; Male; Meta-Analysis as Topic; Network Meta-Analysis; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Research Design; Sildenafil Citrate; Systematic Review as Topic; Tadalafil; Tamsulosin; Vardenafil Dihydrochloride	2020
Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study. Neurourology and urodynamics, 2020, Volume: 39, Issue:5 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Drug Therapy, Combination; Humans; Male; Medicare; Middle Aged; Prostatic Hyperplasia; Retrospective Studies; Tadalafil; United States; Urinary Bladder, Overactive; Urination; Urological Agents	2020
Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients with Benign Prostatic Hyperplasia (KYU-PRO Study). Urologia internationalis, 2020, Volume: 104, Issue:7-8 Topics: Aged; Aged, 80 and over; Diagnostic Self Evaluation; Humans; Male; Nocturia; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Tadalafil; Treatment Outcome	2020
[Combination of 1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of observatory prospective multicenter study]. Urologiia (Moscow, Russia : 1999), 2020, Issue:3 Topics: Adult; Aged; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Moscow; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2020
Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats. European journal of pharmacology, 2020, Sep-05, Volume: 882 Topics: Animals; Fibroblast Growth Factors; Hypertension; Interleukin-6; Male; Malondialdehyde; Phosphodiesterase 5 Inhibitors; Prostate; Prostatic Hyperplasia; Rats, Inbred SHR; Rats, Inbred WKY; Regional Blood Flow; Tadalafil; Transforming Growth Factor beta1	2020
[Effects of Tadalafil 5 mg Once-Daily on Serum Testosterone Level, Erectile Function, and Highly Sensitive C-Reactive Protein Value in Hypogonadal Patients with Lower Urinary Tract Symptoms]. Hinyokika kiyo. Acta urologica Japonica, 2020, Volume: 66, Issue:8 Topics: C-Reactive Protein; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Testosterone; Treatment Outcome	2020
Outcomes of combination therapy with daily tadalafil 5 mg plus tamsulosin 0.4 mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. Minerva urology and nephrology, 2021, Volume: 73, Issue:6 Topics: Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Metabolic Syndrome; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Tadalafil; Tamsulosin	2021
[EVALUATING THE RELATIONSHIP BETWEEN LOWER URINARY TRACT SYMPTOMS AND ENDOTHELIAL FUNCTION USING FLOW-MEDIATED DILATION, AND THE EFFECTS OF TADALAFIL]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2020, Volume: 111, Issue:1 Topics: Aged; Blood Flow Velocity; Endothelium, Vascular; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urinary Bladder, Overactive; Vasodilation	2020
[Effect of Tadalafil SZ on endothelial function in patients with erectile dysfunction]. Urologiia (Moscow, Russia : 1999), 2021, Issue:1 Topics: Adult; Carbolines; Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2021
[Tadalafil Ameliorates Symptoms of Patients with Benign Prostatic Hyperplasia Complicated by Chronic Pelvic Pain Syndrome]. Hinyokika kiyo. Acta urologica Japonica, 2017, Volume: 63, Issue:3 Topics: Humans; Male; Middle Aged; Pelvic Pain; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2017
Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia. Urology, 2017, Volume: 106 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Retrospective Studies; Tadalafil; Treatment Outcome; Urination	2017
Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. The aging male : the official journal of the International Society for the Study of the Aging Male, 2018, Volume: 21, Issue:1 Topics: Aged; Ankle Brachial Index; Endothelium, Vascular; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostate; Prostatic Hyperplasia; Pulse Wave Analysis; Tadalafil	2018
Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia. International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:3 Topics: Humans; Japan; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prognosis; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Severity of Illness Index; Tadalafil; Treatment Outcome; Urination	2018
Re: A Relevant Midterm (12 Months) Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Rate in Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia-A Meta-Analysis. The Journal of urology, 2017, Volume: 198, Issue:6 Topics: Humans; Lower Urinary Tract Symptoms; Male; Placebo Effect; Prostatic Hyperplasia; Tadalafil; Urinary Bladder	2017
Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study). Lower urinary tract symptoms, 2018, Volume: 10, Issue:1 Topics: Aged; Aged, 80 and over; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Symptom Assessment; Tadalafil; Urination; Urodynamics	2018
Penile blood pressure is useful to identify candidates for tadalafil treatment in patients with lower urinary tract symptoms. BJU international, 2019, Volume: 123, Issue:1 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Blood Pressure; Cholinergic Antagonists; Humans; Male; Patient Selection; Penis; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Prostatism; Severity of Illness Index; Tadalafil	2019
Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study. World journal of urology, 2019, Volume: 37, Issue:5 Topics: Aged; Aged, 80 and over; Animals; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Tadalafil; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive; Urodynamics; Urological Agents	2019
Re: Efficacy and Safety of Tadalafil 5 mg Once Daily in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Men Aged ≥75 Years: Integrated Analyses of Pooled Data from Multinational, Randomized, Placebo-Controlled The Journal of urology, 2018, Volume: 200, Issue:4 Topics: Aged; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2018
Re: Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial. The Journal of urology, 2018, Volume: 200, Issue:5 Topics: Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Tamsulosin	2018
Editorial Comment to Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and ta International journal of urology : official journal of the Japanese Urological Association, 2019, Volume: 26, Issue:2 Topics: Double-Blind Method; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Tamsulosin	2019
Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α1 blocker and dutasteride to combination therapy with tadalafil and dutasteride. The aging male : the official journal of the International Society for the Study of the Aging Male, 2020, Volume: 23, Issue:5 Topics: Drug Therapy, Combination; Dutasteride; Erectile Dysfunction; Humans; Japan; Male; Prostatic Hyperplasia; Quality of Life; Retrospective Studies; Tadalafil; Treatment Outcome	2020
Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model. The Prostate, 2019, Volume: 79, Issue:5 Topics: Animals; Disease Models, Animal; Ischemia; Male; Phosphodiesterase 5 Inhibitors; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Tadalafil	2019
Pre-treatment serum testosterone level can be a useful factor to predict the improvement in bladder outlet obstruction by tadalafil for male patients with lower urinary tract symptoms induced by benign prostatic obstruction. The aging male : the official journal of the International Society for the Study of the Aging Male, 2020, Volume: 23, Issue:5 Topics: Aged; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Testosterone; Urinary Bladder Neck Obstruction; Urodynamics	2020
[Safety of tadalafil in patients with cardiovascular comorbidities]. Urologiia (Moscow, Russia : 1999), 2019, Issue:1 Topics: Cardiovascular Diseases; Cardiovascular System; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2019
Tadalafil for benign prostatic hyperplasia. Drug and therapeutics bulletin, 2013, Volume: 51, Issue:8 Topics: Adult; Carbolines; Drug Approval; Erectile Dysfunction; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2013
Should you take an erectile dysfunction drug to also ease urinary woes? We think not. Standard medications to treat the symptoms of an enlarged prostate are still the best first choice for men. Harvard men's health watch, 2013, Volume: 17, Issue:11 Topics: Aged; Aged, 80 and over; Carbolines; Ejaculation; Erectile Dysfunction; Evidence-Based Medicine; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2013
Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. The Journal of urology, 2014, Volume: 191, Issue:2 Topics: Aged; Carbolines; Comorbidity; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2014
Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study. The journal of sexual medicine, 2014, Volume: 11, Issue:2 Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Prostatic Hyperplasia; Surveys and Questionnaires; Tadalafil; Treatment Outcome	2014
Editorial comment to Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:7 Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2014
Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. European journal of pharmacology, 2014, Dec-05, Volume: 744 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Animals; Carbolines; Drug Synergism; Electric Stimulation; Erectile Dysfunction; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Muscle Contraction; Phenylephrine; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Tadalafil	2014
Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials. European urology, 2015, Volume: 67, Issue:1 Topics: Carbolines; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Randomized Controlled Trials as Topic; Regression Analysis; Severity of Illness Index; Tadalafil; Urination	2015
Editorial Comment from Dr Oh-oka to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, random International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:6 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil	2015
Editorial Comment from Dr Masumori to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, rand International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:6 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil	2015
Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis. PloS one, 2015, Volume: 10, Issue:8 Topics: Aged; Data Mining; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Precision Medicine; Prognosis; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil	2015
Do baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil? Andrology, 2015, Volume: 3, Issue:6 Topics: Aged; Biomarkers; Cross-Sectional Studies; Databases, Factual; Estradiol; Humans; Longitudinal Studies; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Predictive Value of Tests; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil; Testosterone; Time Factors; Treatment Outcome	2015
[A Study of the Efficacy of the Additional Administration of Tadalafil in Japanese Men with α1-Blocker-Resistant LUTS/BPH]. Hinyokika kiyo. Acta urologica Japonica, 2016, Volume: 62, Issue:3 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Asian People; Drug Resistance; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Sexual Dysfunction, Physiological; Tadalafil; Treatment Outcome; Urodynamics	2016
Re: Treatment Satisfaction and Clinically Meaningful Symptom Improvement in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia: Secondary Results from a 6-Month, Randomized, Double-Blind Study Compari The Journal of urology, 2016, Volume: 196, Issue:4 Topics: Double-Blind Method; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Personal Satisfaction; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2016
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled cli BJU international, 2017, Volume: 119, Issue:5 Topics: Aged; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Administration Schedule; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil; Treatment Outcome	2017
Tadalafil for male lower urinary tract symptoms improves endothelial function. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:3 Topics: Aged; Ankle Brachial Index; Endothelium, Vascular; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Pulse Wave Analysis; Quality of Life; Tadalafil; Ultrasonography; Urination; Urodynamics; Vasodilator Agents	2017
A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials. Clinical trials (London, England), 2017, Volume: 14, Issue:2 Topics: Bayes Theorem; Drug-Related Side Effects and Adverse Reactions; Humans; Lower Urinary Tract Symptoms; Male; Meta-Analysis as Topic; Models, Statistical; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Tadalafil	2017
EFFECT OF TADALAFIL THAT WAS ADDITIONALLY ADMINISTERED TO PATIENTS RECEIVING AN ALPHA1-BLOCKER IN JAPANESE MEN WITH LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2016, Volume: 107, Issue:1 Topics: Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urodynamics	2016
Re: Efficacy and Safety of Tadalafil 5mg Once Daily in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Men Aged ≥75 years: Integrated Analyses of Pooled Data from Multinational, Randomized, Placebo-controlled European urology, 2017, Volume: 71, Issue:6 Topics: Aged; Carbolines; Double-Blind Method; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2017
Editorial comment on: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. European urology, 2009, Volume: 56, Issue:4 Topics: Carbolines; Drug Administration Schedule; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Tadalafil	2009
Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. La Radiologia medica, 2009, Volume: 114, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Carbolines; Contrast Media; Hemodynamics; Humans; Infusions, Intralesional; Male; Middle Aged; Phosphodiesterase Inhibitors; Prostate; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Ultrasonography, Interventional	2009
Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. Current urology reports, 2010, Volume: 11, Issue:4 Topics: Carbolines; Drug Administration Schedule; Humans; Male; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil; Urodynamics	2010
Editorial comment. Urology, 2010, Volume: 75, Issue:6 Topics: Carbolines; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Quality of Life; Risk Assessment; Tadalafil; Treatment Outcome; Urination Disorders	2010
Editorial comment. Urology, 2010, Volume: 75, Issue:6 Topics: Carbolines; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Prostatic Hyperplasia; Prostatism; Quality of Life; Tadalafil; Treatment Outcome; Urination Disorders	2010
Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. Endocrinology, 2010, Volume: 151, Issue:8 Topics: Carbolines; Cell Proliferation; Cell Transdifferentiation; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Down-Regulation; Drug Evaluation, Preclinical; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Humans; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Prostate; Prostatic Hyperplasia; RNA, Small Interfering; Stromal Cells; Tadalafil; Treatment Outcome	2010
Tadalafil (Cialis) for signs and symptoms of benign prostatic hyperplasia. The Medical letter on drugs and therapeutics, 2011, Nov-14, Volume: 53, Issue:1377 Topics: Carbolines; Clinical Trials as Topic; Drug Costs; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2011
Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or α-adrenoceptor antagonist? BJU international, 2012, Volume: 109, Issue:7 Topics: Adrenergic alpha-Antagonists; Carbolines; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil	2012
Monotherapy with α-blocker or phosphodiesterase 5 inhibitor for lower urinary tract symptoms? European urology, 2012, Volume: 61, Issue:5 Topics: Adrenergic alpha-1 Receptor Antagonists; Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Vasodilator Agents	2012
Erectile dysfunction drug approved to treat BPH symptoms. Mayo Clinic health letter (English ed.), 2012, Volume: 30, Issue:4 Topics: Carbolines; Drug Approval; Erectile Dysfunction; Humans; Male; Prostatic Hyperplasia; Tadalafil; United States; United States Food and Drug Administration; Vasodilator Agents	2012
Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. The journal of sexual medicine, 2012, Volume: 9, Issue:9 Topics: Adrenergic alpha-1 Receptor Antagonists; Carbolines; Electric Stimulation; Humans; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Nitric Oxide Donors; Nitroprusside; Phosphodiesterase 5 Inhibitors; Prostate; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin; Urinary Bladder	2012
Editorial Comment to tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. International journal of urology : official journal of the Japanese Urological Association, 2013, Volume: 20, Issue:2 Topics: Carbolines; Humans; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Sulfonamides; Tadalafil; Tamsulosin	2013
Reply from Authors re: Steven A. Kaplan. Tadalafil for the Treatment of Benign Prostatic Hyperplasia: When the Moment Does Not Add Up. Eur Urol 2013;63:517-8: Tadalafil in the Treatment of Men with Lower Urinary Tract Symptoms and/or Erectile Dysfunction European urology, 2013, Volume: 63, Issue:3 Topics: Carbolines; Evidence-Based Medicine; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2013
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU international, 2006, Volume: 98, Issue:6 Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatic Hyperplasia; Prostatism; Purines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride	2006